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Essentials
• Predictive ability of pro-hemostatic Gas6 for recurrent
venous thromboembolism (VTE) is unknown.
• We measured Gas6 levels in 864 patients with VTE
over 3 years.
• High Gas6 (> 157%) at diagnosis is associated with
VTE recurrence, major bleeding and mortality.
• Gas6 plasma levels measured 12 months after the index
VTE are discriminatory for VTE recurrence.
Summary. Background: Growth arrest-specific gene 6
(Gas6) is a prohemostatic protein with an unknown predic-
tive ability for recurrent venous thromboembolism (VTE).
In the elderly, VTE results in higher mortality but does not
have a higher rate of recurrence than in younger patients.
Consequently, anticoagulation management in the elderly is
challenging. Objective: To prospectively investigate the
performance of Gas6 in predicting VTE recurrence, major
bleeding and mortality in the elderly. Methods: Consecu-
tive patients aged ≥ 65 years with acute VTE were fol-
lowed for a period of 3 years. Primary outcomes were
symptomatic VTE recurrence, major bleeding, and mor-
tality. Plasma Gas6 was measured with ELISA. Results:
Gas6 levels were measured in 864 patients at the time of
the index VTE (T1) and, in 70% of them, also 12 months
later (T2). The Gas6 level at T1 was discriminatory for
VTE recurrence (C-statistic, 0.56; 95% confidence interval
[CI] 0.51–0.62), major bleeding (0.60, 95% CI 0.55–0.65)
and mortality (0.69, 95% CI 0.65–0.73) up to 36 months.
VTE recurrence up to 24 months after T2 was discrimi-
nated by the Gas6 level at T2 (0.62, 95% CI 0.54–0.71).
High Gas6 levels (> 157%) and continuous Gas6 levels at
T1 were associated with VTE recurrence up to 6 months
and 12 months, respectively. Conclusions: In elderly
patients, a high Gas6 level is associated with higher risks
of VTE recurrence, major bleeding, and death. These find-
ings support further studies to assess the performance of
Gas6 in adjusting the length of anticoagulation.
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Introduction
Venous thromboembolism (VTE), comprising deep vein
thrombosis (DVT) and pulmonary embolism (PE), repre-
sents a worldwide major health issue, and is a leading
cause of cardiovascular death [1]. VTE incidence rises
with age [2–5]. In the elderly population, VTE results in
higher mortality but does not have a higher rate of recur-
rence than in younger patients [4]. Elderly patients more
often present with comorbidities, and therefore a higher
risk of bleeding [4]. Consequently, management of the
anticoagulation in the elderly constitutes a challenge.
Because the risk of VTE recurrence is greatest in the first
6–12 months following the initial event and progressively
decreases afterwards [6], the benefit of extended anticoagu-
lation may be exceeded by the risk of clinically important
bleeding [7–12].
Growth arrest-specific gene 6 (Gas6), the product of the
gene GAS6 [13], is a secreted vitamin K-dependent protein.
The Gas6 plasma level is known to be elevated in a variety
of clinical conditions, including inflammation or sepsis [14–
18], obesity [19], chronic renal failure, and cancer [20].
Importantly, no change in the Gas6 plasma level with
increasing age was previously observed [21]. Nevertheless,
the Gas6 level progressively decreased with increasing Inter-
national Normalized Ratio under warfarin therapy [21].
Gas6 has multiple functions, including regulation of cell
growth [13] and inflammation [22]. It also has effects on
platelet function and coagulation, enhancing platelet aggre-
gation and tissue factor expression in endothelial cells, as
well as promoting the recruitment of platelets and leuko-
cytes to the endothelial cell membrane [23–28]. In mice,
the absence of Gas6 is protective against thrombosis with-
out causing excessive bleeding, pointing to Gas6 as an
attractive target for antithrombotic therapy [23,25].
In a cross-sectional study including 279 patients and 79
controls, Blostein et al. [29] measured a higher Gas6
plasma level in patients 4 months after VTE than in
healthy controls. In addition, they observed that subjects
with elevated Gas6 levels in plasma had an increased risk
of VTE as compared with those with lower Gas6 levels
after adjustment for age, sex, medications, and comor-
bidities. However, elevated Gas6 plasma levels were not
predictive of VTE recurrence [29]. Finally, most of the
patients included in this study were aged < 65 years.
Here, in a cohort of 864 patients aged ≥ 65 years with
VTE, we prospectively investigated the performance of
Gas6 plasma levels at admission and 1 year after the
index VTE in predicting the risk of VTE recurrence,
major bleeding, and mortality.
Methods
Cohort sample
The study was conducted between September 2009 and
December 2013 as part of the Swiss Cohort of Elderly
Patients with VTE (SWITCO65+), which was a prospec-
tive multicenter cohort study to assess medical outcomes
and quality of life in elderly patients with acute VTE
from all five university hospitals and from four high-
volume non-university hospitals in Switzerland [30].
Consecutive patients aged ≥ 65 years with acute VTE
were identified in the inpatient and outpatient services of
all participating study sites, and followed for a period of
3 years. We defined DVT as acute onset of leg pain or
swelling plus incomplete compressibility of a venous seg-
ment on ultrasonography or an intraluminal filling defect
on contrast venography [31].
Because iliac veins and the inferior vena cava may be
technically difficult to compress, additional diagnostic cri-
teria for iliac/caval DVT comprised abnormal duplex flow
patterns compatible with thrombosis or an intraluminal
filling defect on spiral computed tomography (CT) or
magnetic resonance imaging venography [32–34].
Given that ultrasonography has reduced sensitivity and
specificity for distal DVT [35], patients with isolated distal
DVT were included only if the incompressible distal deep
vein transverse diameter was at least 5 mm [36,37].
Symptomatic PE was defined as: acute onset of dysp-
nea, chest pain, or syncope, coupled with a new high-
probability ventilation/perfusion lung scan; a new
contrast filling defect on spiral CT or pulmonary angiog-
raphy; or the new documentation of a proximal DVT
either by venous ultrasound or by contrast venography
[37,38]. Radiographic studies used to diagnose VTE were
interpreted by on-site vascular specialists or radiologists.
Exclusion criteria were inability to provide informed
consent (i.e. severe dementia), conditions incompatible
with follow-up (i.e. terminal illness or place of residence
too far from the study center), insufficient German-speak-
ing or French-speaking ability, thrombosis at a site other
than a lower limb, and catheter-related thrombosis.
Treatment of VTE, e.g. the type of anticoagulant used
(i.e. parenteral anticoagulant followed by vitamin K
antagonists, parenteral anticoagulant alone, or direct oral
anticoagulant), the duration of the anticoagulation, and
the prescription of compression stocking, was entirely left
to the discretion of the managing physicians.
Eligible patients were approached for informed consent
to participate in the study. The ethics committees at each
study site approved the study, and written informed con-
sent was obtained from all participants. A detailed
description of the study methods has previously been
published [30].
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Data collection
For all enrolled patients, trained study nurses prospectively
collected baseline demographic information (age and sex),
type, history and complication of VTE (distal DVT, proxi-
mal DVT, overt PE, presence of post-thrombotic syndrome,
prior VTE, provoked index VTE, or cancer-related VTE),
concomitant use of estrogen therapy during the past
3 months, immobilization during the last 3 months, major
surgery during the last 3 months, comorbid conditions (his-
tory of major bleeding, chronic liver disease, renal disease,
chronic or acute heart failure, cerebrovascular disease, dia-
betes mellitus, body mass index of > 30, acute rheumatic dis-
ease during the last 3 months, inflammatory bowel disease,
or severe infection or sepsis during the last 3 months), a high
risk of falling, laboratory findings (anemia or low platelet
count), concomitant use of antiplatelet drugs, arterial hyper-
tension, a heart rate of ≥ 110 beats min1, systolic blood
pressure of < 100 mmHg, a respiratory rate of ≥ 30 min1,
a temperature of < 36 °C, arterial oxygen saturation of
< 90%, and VTE-related treatment, by the use of standard-
ized data collection forms. Follow-up included one tele-
phone interview and two face-to-face evaluations during the
first year of study participation, and then semi-annual con-
tacts, alternating between face-to-face evaluations (clinic vis-
its or home visits in house-bound patients) and telephone
calls, as well as periodic reviews of the patient’s hospital
chart. During each visit/contact, study nurses interviewed
patients to obtain information about the date and type of
clinical events (recurrent VTE, bleeding, or death). If a clini-
cal event had occurred, this information was complemented
by reviewing medical charts and interviewing patients’ pri-
mary-care physicians and family members. Collected data
were recorded on standardized forms.
Blood samples
Blood was collected after minimal venostasis into 1/9 of
its volume of 0.0160 M trisodium citrate (Sarstedt;
Thermo Fischer Scientific, Waltham, Massachusetts,
USA) at the time of the index VTE diagnosis and
12 months later [39]. Citrated platelet-poor plasma (PPP)
was prepared by centrifugation for 10 min at 2700 9 g
and room temperature, and recentrifugation of the super-
natant plasma for 10 min at 2700 9 g to remove remain-
ing platelets [39]. The resulting citrated PPP was stored in
aliquots of 2 mL at  80 °C within 1 h of blood collec-
tion [39]. Citrated PPP was used for Gas6 ELISA.
Gas6 ELISA
To measure Gas6, we used the ELISA method developed
by Clauser et al. [40], with some modifications [17]. Wells
from 96-well plates (Maxisorp; Nunc, N€umbrecht, Ger-
many) were coated with 100 lL per well of polyclonal goat
anti-human Gas6 antibody (AB885; R&D Systems,
Abington, UK) diluted in 0.1 M NaHCO3 (pH 8.2), and
incubated overnight at 4 °C. After two washes with phos-
phate-buffered saline (PBS)–Tween 0.05%, 100 lL of
PBS–bovine serum albumin (BSA) 1%/5% was added to
the wells, and plates were incubated for 2 h at room tem-
perature. After three washes, samples diluted 50-fold and
100-fold and a normal plasma serial dilution with PBS–
BSA 1% were added to the wells, and this was followed by
overnight incubation at 4 °C. After three washes, 100 lL
of biotinylated polyclonal goat antibody (BAF885; R&D
Systems) was added to each well, and plates were left for
2 h at room temperature. Signals were amplified with
avidin–horseradish peroxidase (BD Pharmingen, Oxford,
UK), and plates were incubated for 20 min at 37 °C.
Finally, o-phenylenediamine dihydrochloride (Sigma-
Aldrich St. Louise, Missouri, USA) was added. Reactions
were stopped by the addition of 50 lL of 3 M HCl. Absor-
bance was measured at 492 nm, and the results were
expressed as percentages relative to normal plasma, with its
serial dilution as standard curve [17,40]. This ELISA was
specific for human Gas6, with no cross-reactivity with
human protein S.
D-dimer
D-dimer was measured by ELISA (Vidas D-dimer exclu-
sion test; bioMerieux, Marcy-l’Etoile, France).
Outcome variables
We defined objectively confirmed, symptomatic VTE
recurrence, major bleeding and overall mortality up to
3 years as primary study outcomes.
VTE recurrence was defined as a fatal or new non-fatal
PE or new DVT [41]. The diagnosis of recurrent VTE
during follow-up was established according to the follow-
ing criteria: for DVT, on the basis of abnormal results on
ultrasonography; and for PE, on the basis of CT or
angiography showing new intraluminal defects, or on the
basis of a ventilation–perfusion lung scan showing a high-
probability pattern with new perfusion defects. A new
proximal DVT, based on abnormal results on ultrasonog-
raphy, associated with new PE symptom(s) (shortness of
breath, chest pain, and syncope) was also considered as
recurrent PE.
Major bleeding was defined as fatal bleeding, symp-
tomatic bleeding at critical sites (intracranial, intraspinal,
intraocular, retroperitoneal, intra-articular, pericardial, or
intramuscular with compartment syndrome), or clinically
overt bleeding with a reduction in hemoglobin level of at
least 20 g L1, or leading to transfusion of two or more
units of packed red blood cells [42].
We assessed the outcomes by using patient or proxy inter-
views, interview of the patient’s primary-care physician,
and/or hospital chart review [30]. A committee of three
blinded clinical experts confirmed all outcomes and classified
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all deaths as being definitely attributable to PE, possibly
attributable to PE (e.g. sudden death without an obvious
cause), attributable to major bleeding, or attributable to
another cause [30]. The final classification was made on the
basis of the full consensus of this committee [30].
Statistical analyses
We compared the baseline characteristics of patients in rela-
tion to elevated plasma Gas6 (above versus below the med-
ian) by using the chi-squared test and the non-parametric
Wilcoxon rank-sum test as appropriate. We calculated inci-
dence rates of a first VTE recurrence, a first major bleed or
death up to 3 years after the index event in relation to the
level of Gas6. Gas6 was categorized into low, medium and
high levels on the basis of lower and upper quartiles. We
estimated the cumulative incidence of these outcomes by
using the Kaplan–Meier method, and compared survivor
functions across groups by using the log-rank test.
The discriminative power of Gas6 for predicting VTE
recurrence, major bleeding and mortality was assessed by
the use of Harrell’s C concordance statistic.
Associations between Gas6 and the time to a first VTE
recurrence and major bleeding were assessed by the use of
competing risk regression accounting for non-PE-related
and non-bleeding-related death, respectively, as a compet-
ing event, according to the method of Fine and Gray
[43]. The method yields subhazard ratios with correspond-
ing 95% confidence intervals (CIs) and P-values for the
failure event of primary interest. For mortality, an ordi-
nary Cox regression with robust standard errors was cal-
culated. We adjusted the model for previously published
predictors of VTE recurrence or major bleeding
[6,41,42,44–52]. For overall mortality, analyses were
adjusted for age, gender, cancer, provoked VTE, prior
VTE, overt PE, renal disease, history of major bleeding,
heart failure, chronic lung disease, elevated heart rate,
low blood pressure, low oxygen and periods of anticoagu-
lation as a time-varying covariate [49,53].
All analyses were performed with STATA 14 (Stata Cor-
poration, College Station, Texas, USA).
Results
Study sample
Of 1003 enrolled patients aged ≥ 65 years with acute
VTE, we excluded 139 patients at the time of index VTE
Screened patients aged ≥ 65 years
with symptomatic VTE
n = 1863
462 patients excluded*
Site other than lower limb n = 21
Catheter-related thrombosis n = 7
Insufficient German-speaking or 
French-speaking ability n = 51
Follow-up not possible n = 192
Inabililty to provide consent n = 398
*Multiple reasons for exclusion may apply
139 patients excluded from analysis
Patients not allowing use of data n = 8
Early withdrawals (within 1 day) n = 4
No Gas6 result n = 127
Patients enrolled in SWITCO65+
n = 1003
n = 864
Patients analyzed
Fig. 1. Flow diagram of patients included in the study. Gas6, growth arrest-specific gene 6; VTE, venous thromboembolism.
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diagnosis (eight patients did not allow the use of data,
four withdrew their consent within 1 day, and 127 had no
Gas6 measurement), leaving a study sample of 864
patients (Fig. 1). Of these patients, 601 (69.6%) had Gas6
measurement 12 months after the index VTE.
Characteristics at the time of the index VTE diagnosis
are shown in Table 1. Overall, 476 patients (44.9%) were
women, and the median age was 75.0 years (interquartile
range [IQR] 69.0–81.0 years). Five hundred and
ninety-nine patients (69.3%) presented with an index PE.
Two hundred and fifty-one patients (29.1%) had experi-
enced prior VTE. Five hundred and twenty-two patients
(60.4%) had an unprovoked index VTE, 185 (21.4%) had
provoked VTE, and 157 (18.2%) had cancer-related VTE.
Patients with an unprovoked index VTE or with prior
VTE were more likely to present with PE (70%) than
with proximal (24%) or distal DVT (6%) only. PE was
more frequent in patients with unprovoked VTE (72%)
Table 1 Patient characteristics at the time of the index venous thromboembolism (VTE) by growth arrest-specific gene 6 (Gas6) plasma level
(above versus below or at the median)
Characteristic* All
Gas6 level above
median (> 129%)
Gas6 level below or at
median (≤ 129%)
P-valuen (%) or median (IQR) n (%) or median (IQR)
Total number of patients 864 435 429
Patient age (years) 75.0 (69.0–81.0) 76.0 (70.0–82.0) 74.0 (69.0–80.0) 0.001
Female sex 388 (44.9) 207 (47.6) 181 (42.2) 0.111
VTE location
Distal DVT only 70 (8.1) 29 (6.7) 41 (9.6) 0.053
Proximal DVT 195 (22.6) 111 (25.5) 84 (19.6)
Pulmonary embolism 599 (69.3) 295 (67.8) 304 (70.9)
Type of VTE†
Unprovoked 522 (60.4) 242 (55.6) 280 (65.3) < 0.001
Provoked 185 (21.4) 92 (21.1) 93 (21.7)
Cancer-related* 157 (18.2) 101 (23.2) 56 (13.1)
Estrogen therapy during the last 3 months* 27 (3.1) 9 (2.1) 18 (4.2) 0.073
Immobilization during the last 3 months 190 (22.0) 115 (26.4) 75 (17.5) 0.001
Major surgery during the last 3 months 131 (15.2) 72 (16.6) 59 (13.8) 0.251
Prior VTE 251 (29.1) 125 (28.7) 126 (29.4) 0.837
Presence of PTS*,‡ 453 (52.4) 251 (57.7) 202 (47.1) 0.003
History of major bleeding* 89 (10.3) 54 (12.4) 35 (8.2) 0.039
Chronic liver disease 13 (1.5) 10 (2.3) 3 (0.7) 0.053
Renal disease§ 170 (19.7) 97 (22.3) 73 (17.0) 0.051
Chronic or acute heart failure 103 (11.9) 57 (13.1) 46 (10.7) 0.280
Cerebrovascular disease (stroke, TIA) 84 (9.7) 44 (10.1) 40 (9.3) 0.695
Diabetes mellitus 137 (15.9) 79 (18.2) 58 (13.5) 0.062
BMI > 30* 201 (23.3) 107 (24.6) 94 (21.9) 0.360
High risk of falling*,¶ 406 (47.0) 233 (53.6) 173 (40.3) < 0.001
Acute rheumatic disease during the last 3 months 29 (3.4) 17 (3.9) 12 (2.8) 0.365
Inflammatory bowel disease 31 (3.6) 9 (2.1) 22 (5.1) 0.016
Severe infection or sepsis during the last 3 months 71 (8.2) 42 (9.7) 29 (6.8) 0.121
Anemia*,** 335 (38.8) 206 (47.4) 129 (30.1) < 0.001
Platelet count of < 150 G L1* 132 (15.3) 78 (17.9) 54 (12.6) 0.039
Antiplatelet therapy†† 275 (31.8) 147 (33.8) 128 (29.8) 0.212
Arterial hypertension 552 (63.9) 289 (66.4) 263 (61.3) 0.116
Heart rate of ≥ 110 beats min1* 79 (9.1) 49 (11.3) 30 (7.0) 0.031
Systolic BP of < 100 mmHg* 28 (3.2) 13 (3.0) 15 (3.5) 0.664
Respiratory rate of ≥ 30 min1* 28 (3.2) 16 (3.7) 12 (2.8) 0.469
Temperature of < 36 °C* 65 (7.5) 27 (6.2) 38 (8.9) 0.119
Arterial oxygen saturation of < 90%* 93 (10.8) 62 (14.3) 31 (7.2) 0.001
BP, blood pressure; BMI, body mass index; DVT, deep vein thrombosis; IQR, interquartile range, PTS, post-thrombotic syndrome; TIA, tran-
sient ischemic attack. *Values were missing for estrogen therapy during the last 3 months (0.1%), presence of PTS (1.9%), history of major
bleeding (0.1%), BMI > 30 (0.6%), high risk of falling (0.1%), anemia (5.8%), platelet count (5.8%), heart rate of ≥ 110 beats min1 (2.1%),
systolic BP of < 100 mmHg (1.6%), respiratory rate of ≥ 30 min1 (21.1%), temperature of < 36°C (7.8%), and arterial oxygen saturation of
< 90% (21.3%). †Provoked VTE is defined as immobilization, surgery or estrogen therapy during the last 3 months. Cancer is defined as any
solid or hematological cancer that required chemotherapy, radiation therapy, surgical treatment or palliative treatment during the last
3 months. ‡Defined as a Villalta score of > 5 or the presence of an ulcer on the left or right side. §Chronic renal disease or creatinine clearance
of < 30 mL min1. ¶Defined as answering yes to at least one screening question: (i) Did you fall during the last year? (ii) Did you notice any
problem with gait, balance, or mobility? **Anemia: a hemoglobin level of < 12 g dL1 for females or of < 13 g dL1 for males. ††Defined as
antiplatelet therapy such as aspirin 100–300 mg daily, clopidogrel, prasugrel or aspirin/dipyridamole at the time of the index VTE.
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than in patients with provoked (66%) or cancer-related
(64%) VTE (P = 0.01). Twelve months after the index
VTE, 432 patients (50%) were still receiving anticoagula-
tion, most of them with vitamin K antagonists.
Gas6 plasma levels in study samples
At the time of the index VTE diagnosis, the median Gas6
level was 129.3% (IQR 108.9–156.6) (T1 in Fig. 2). Patients
with elevated Gas6 levels (> 129%) at the time of the index
VTE were slightly older (median age of 76 years versus
74 years, P = 0.001). However, the correlation between Gas6
level and age was weak both at the time of the index VTE
(Spearman correlation, rs = 0.12) and 12 months later
(rs = 0.09). Patients with elevated Gas6 levels at the time of
the index VTE diagnosis were more likely to have cancer-
related VTE. They were also more immobilized during the
last 3 months and showed higher prevalences of post-throm-
botic syndrome, history of major bleeding, anemia, thrombo-
cytopenia, heart rate of ≥ 110 beats min1, and oxygen
saturation of < 90% (Table 1). In contrast, these patients
were less likely to be still receiving oral anticoagulation
12 months after the index VTE (180 [41.4%] patients with
Gas6 levels above the median versus 230 [53.6%] patients
with Gas6 levels below or at the median, P < 0.001). Interest-
ingly, patients with inflammatory bowel disease were more
likely to have a lower Gas6 level (P = 0.016). Twelve months
after the index VTE, the median Gas6 level was 93%
(IQR 77.1–111.7) (T2 on Fig. 2). However, at this time point,
the median Gas6 level was lower in patients receiving antico-
agulation than in patients not receiving anticoagulation
(86.1% [IQR 70.4–107.3] versus 100.2% [IQR 85.3–116.8],
P < 0.001).
Gas6 plasma levels were generally lower 12 months
after the index VTE (T2) than at the time of the index
VTE (T10 versus T2, P < 0.001; Fig. 2). In a minority of
patients (n = 97, 11%), the Gas6 level increased from the
time of VTE diagnosis to 12 months later.
The correlation between Gas6 and D-dimer was weak,
both at the time of the index VTE (Spearman correlation,
rs = 0.06) and 12 months later (rs = 0.24).
Incidence rates of VTE recurrence, major bleeding, and
mortality
After a follow-up of 3 years, 100 patients had developed
recurrent VTE, resulting in an incidence rate of 5.6 per
100 person-years (95% CI 4.6–6.8). During the same per-
iod, 170 of 864 patients had died (mortality rate of 9.0
per 100 person-years; 95% CI 7.8–10.5). The mortality
rate was higher during the initial 6 months, whereas the
VTE recurrence rate remained stable over the observation
period (Table S1). During the whole follow-up, the inci-
dence rates of VTE recurrence and major bleeding were
higher in patients with high Gas6 levels than in patients
with medium or low Gas6 levels measured at the time of
the index VTE (Table S1). Likewise, the 2-year cumula-
tive incidence of VTE recurrence was higher for patients
with high (> 157%) than for patients with medium (109–
157%) and low (< 109%) Gas6 levels measured at the
time of the index VTE, although not significantly
(P = 0.087) (Fig. 3A). The 2-year cumulative incidence of
major bleeding was higher for patients with high
(> 157%) than for patients with medium (109–157%) and
low (< 109%) Gas6 levels measured at the time of the
index VTE (P = 0.0004) (Fig. 3B).
The 2-year cumulative incidence rates of overall mortal-
ity were 7%, 15% and 35% (P < 0.001) for patients with
low, medium and high Gas6 levels, respectively (Fig. 3C).
Discriminative power of Gas6 levels for outcomes
In order to evaluate the discriminative power of Gas6
levels, C-statistic (95% CI) values were calculated
(Table 2). Gas6 levels measured at the time of the index
VTE were discriminatory for VTE recurrence, major
bleeding and mortality up to 36 months.
The Gas6 level measured 12 months after the index
VTE was discriminatory for VTE recurrence up
24 months. In contrast, when measured 12 months later,
the Gas6 level was not discriminatory for major bleeding
and mortality up to 24 months (Table 2).
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Fig. 2. Growth arrest-specific gene 6 (Gas6) plasma levels at the time
of venous thromboembolism (VTE) diagnosis and 12 months later.
Box-plot of Gas6 levels presented as median with interquartile range
(IQR) and whiskers with a maximum length of 1.5 IQR. T1, Gas6
level at the time of the index VTE of all patients (Gas6: n = 864).
T10, Gas6 level at the time of the index VTE of patients who also
had the Gas6 level measured at T2 (Gas6: n = 601). T10 and T were
compared using the Wilcoxon matched pairs signed-ranks test. The
P-values indicate that the differences were significant. The Spearman
correlation between T10 and T2 was rs = 0.33 for Gas6.
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Association between Gas6 plasma levels and outcomes
High Gas6 levels (> 157%) measured at the time of the
index VTE were associated with an increased risk of VTE
recurrence up to 6 months (Table 3), and an increased
risk of major bleeding up to 36 months (crude analysis)
(Table 4). In continuous analysis (log-transformed Gas6
levels), the risk of VTE recurrence was increased up to
12 months (Table 3), and the risk of major bleeding was
increased up to 36 months (crude analysis) (Table 4).
In addition, medium (109–157%) and high Gas6 levels
were associated with increased overall mortality up to
36 months (Table 5).
These associations also remained after adjustment for
potential confounding factors for the risk of VTE recur-
rence and overall mortality (Tables 3 and 5).
Regarding the risk of major bleeding, only the associa-
tion with high Gas6 levels measured at the time of the
index VTE remained up to 6 months after adjustment for
potential confounding factors (Table 4).
We assessed the relationship between continuous log-
transformed Gas6 values and risks of VTE recurrence
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Fig. 3. Cumulative incidence rates of venous thromboembolism
(VTE), major bleeding and mortality for strata of growth arrest-spe-
cific gene 6 (Gas6). The cumulative incidence rates of VTE (A),
major bleeding (B) and mortality (C) for strata of Gas6 levels were
estimated with the Kaplan–Meier method, and survivor functions
across groups were compared by use of the log-rank test. Gas6 levels
were categorized on the basis of the lower and upper quartiles as
low (< 109%), medium (109–157%), and high (> 157%).
Table 2 Discriminative power of growth arrest-specific gene 6 (Gas6)
plasma level for outcomes
No. of
events/no.
of patients
C-statistics (95%
confidence
interval)
P-
value*
From the time of the index
VTE (T1) onwards using measurements performed at the
time of VTE diagnosis (T1)
Gas6 at the time of VTE diagnosis
VTE recurrence
Up to 6 months 24/864 0.67 (0.57–0.78) 0.001
Up to 12 months 48/864 0.61 (0.52–0.69) 0.010
Up to 24 months 83/864 0.58 (0.52–0.64) 0.010
Up to 36 months 100/864 0.56 (0.51–0.62) 0.031
Major bleeding
Up to 6 months 62/864 0.62 (0.55–0.69) < 0.001
Up to 12 months 82/864 0.60 (0.54–0.66) 0.001
Up to 24 months 103/864 0.60 (0.55–0.65) < 0.001
Up to 36 months 118/864 0.60 (0.55–0.65) < 0.001
Overall mortality
Up to 6 months 77/864 0.73 (0.67–0.78) < 0.001
Up to 12 months 97/864 0.71 (0.65–0.76) < 0.001
Up to 24 months 149/864 0.70 (0.66–0.74) < 0.001
Up to 36 months 170/864 0.69 (0.65–0.73) < 0.001
From 12 months after the index VTE (T2) onwards using
measurements performed 12 months after the index VTE (T2)
Gas6 12 months after the index VTE
VTE recurrence
Up to 12 months 32/601 0.66 (0.56–0.75) 0.002
Up to 24 months 49/601 0.62 (0.54–0.71) 0.003
Major bleeding
Up to 12 months 18/601 0.58 (0.43–0.72) 0.294
Up to 24 months 32/601 0.57 (0.47–0.68) 0.173
Overall mortality
Up to 12 months 33/601 0.57 (0.47–0.68) 0.181
Up to 24 months 48/601 0.56 (0.48–0.65) 0.159
VTE, venous thromboembolism. *The P-value is from a test of the
null hypothesis of no discrimination (i.e. a C-statistics of 0.5).
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and overall mortality by using fractional polynomial com-
peting risk and Cox proportional hazards models, which
showed that (sub)-hazards and Gas6 levels increased line-
arly (Fig. S1).
The findings of the sensitivity analyses revealed that
these associations also remained after the exclusion of
patients with cancer (Table S2) or with cancer and pro-
voked VTE (Table S3). Moreover, in the subgroup of
patients not receiving oral anticoagulation 12 months
after the index VTE, continuous (log-transformed) Gas6
levels were associated with VTE recurrence up to
12 months (Table S4). This association also remained
after adjustment for potential confounding factors
(Table S5). Finally, medium, high and continuous (log-
transformed) Gas6 levels were associated with increased
mortality up to 36 months (Table 5).
Discussion
We prospectively followed 864 elderly patients with VTE
for a period of 3 years, and observed that patients with
higher Gas6 levels were more likely to have cancer-
related VTE and comorbidities. Our findings are consis-
tent with previous publications reporting high Gas6
levels in a number of clinical conditions, most of them
associated with inflammation and organ damage
[14,17,54,55].
Our data showed that an elevated Gas6 level was inde-
pendently associated with recurrent VTE up to
12 months, with major bleeding up to 6 months and with
mortality up to 36 months after the index VTE. Consider-
ing that patients with more comorbidities were more
likely to have higher Gas6 levels, neither the association
with VTE recurrence, the association with major bleeding
nor the association with overall mortality was surprising.
However, the observed association remained significant
after adjustment for a large number of comorbidities
(Table 3–5). The Gas6 level was also still associated with
VTE recurrence and mortality after the exclusion of
patients with cancer (Table S2) or with cancer and pro-
voked VTE (Table S3). Because Gas6 is a prohemostatic
protein [23–25], we may assume that the association
Table 3 Association between growth arrest-specific gene 6 (Gas6) plasma level and venous thromboembolism (VTE) recurrence – from the time
of the index VTE (T1) onwards using Gas6 measured at the time of VTE diagnosis (T1)
n/N (%)
Crude subhazard ratio
(95% confidence interval) P-value
Adjusted subhazard ratio
(95% confidence interval) P-value
Up to 6 months
Gas6 at the time of the index VTE (categorized)
Low (< 109%) 2/216 (0.9) Reference Reference
Medium (109–157%) 11/435 (2.5) 2.77 (0.61–12.51) 0.185 2.95 (0.62–13.95) 0.172
High (> 157%) 11/213 (5.2) 5.74 (1.27–25.95) 0.023 6.65 (1.44–30.80) 0.015
Log-transformed Gas6 at the time of the index VTE
Continuous (per log unit) 24/864 (2.8) 4.71 (1.98–11.19) < 0.001 5.04 (2.14–11.88) < 0.001
Up to 12 months
Gas6 at the time of the index VTE (categorized)
Low (< 109%) 8/216 (3.7) Reference Reference
Medium (109–157%) 23/435 (5.3) 1.46 (0.65–3.25) 0.355 1.50 (0.66–3.40) 0.335
High (> 157%) 17/213 (8.0) 2.26 (0.98–5.23) 0.056 2.42 (1.00–5.89) 0.051
Log-transformed Gas6 at the time of the index VTE
Continuous (per log unit) 48/864 (5.6) 2.42 (1.12–5.24) 0.025 2.47 (1.08–5.64) 0.032
Adjustments: VTE recurrence was adjusted for age, cancer, provoked VTE, prior VTE, overt pulmonary embolism, renal disease and periods
of anticoagulation (oral or parenteral anticoagulation) as a time-varying covariate [6,41,44–52].
Table 4 Association between growth arrest-specific gene 6 (Gas6) plasma level and major bleeding up to 6 months
n/N (%) Crude SHR (95% CI) P-value Adjusted SHR (95% CI) P-value
From the time of the index VTE (T1) onwards using Gas6 measured at the time of VTE diagnosis (T1)
Gas6 at the time of the index VTE (categorized)
Low (< 109%) 7/216 (3.2) Reference Reference
Medium (109–157%) 32/435 (7.4) 2.33 (1.03–5.28) 0.043 2.07 (0.89–4.82) 0.093
High (> 157%) 23/213 (10.8) 3.47 (1.49–8.10) 0.004 2.58 (1.04–6.37) 0.040
Log-transformed Gas6 at the time of the index VTE
Continuous (per log unit) 62/864 (7.2) 2.79 (1.42–5.46) 0.003 2.05 (0.95–4.41) 0.067
CI, confidence interval; SHR, subhazard ratio; VTE, venous thromboembolism. Adjustments: major bleeding was adjusted for age, cancer, pro-
voked VTE, prior VTE, overt pulmonary embolism, renal disease, history of major bleeding, anemia, antiplatelet therapy and periods of anti-
coagulation as a time-varying covariate [51,59–73].
© 2018 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals, Inc. on behalf of International Society on
Thrombosis and Haemostasis.
Gas6, VTE recurrence and mortality in the elderly 313
between high Gas6 levels and VTE recurrence might be
at least partly causal.
Another important finding of this study is that Gas6
levels measured at the time of diagnosis were discrimina-
tory for VTE recurrence and mortality. In addition, Gas6
levels measured 12 months after the index VTE were dis-
criminatory only for VTE recurrence. A previous study
comprising a lower number of patients than this study
did not demonstrate the predictive ability of Gas6 levels
for VTE recurrence [29].Thus, the data of the present
study point to an elevated Gas6 level as an independent
predictor for VTE recurrence, major bleeding and mortal-
ity up to 36 months in the elderly. The Gas6 level might
therefore be useful in adjusting the intensity of surveil-
lance in this group of high-risk patients. However, before
considering the Gas6 level as an additional marker with
which to predict recurrence and guide therapy, the Gas6
level would need to be compared with or integrated into
established risk scores such as the DASH [56], HER-
DOO-2 [57] and Vienna [58] scores.
Our study has some limitations. First, the scope of the
study was limited to elderly patients, and 18.2% of them
had cancer; the mortality resulting from comorbid dis-
eases is naturally higher than the VTE recurrence rate, as
persons with limited life-expectancy often do not have the
time to develop recurrent VTE. Thus, it is indeed unclear
whether the results can be extrapolated to younger per-
sons with VTE. In addition, although the Gas6 plasma
level was previously reported not to be influenced by age
[21], both its predictive ability for VTE recurrence and its
association with VTE recurrence would need to be stud-
ied in younger patients. Second, the Gas6 level was previ-
ously reported to be elevated in several other medical
conditions. Nevertheless, in this study, we were able to
demonstrate that the association between the Gas6 level
and VTE recurrence and mortality remained after
adjustment for these conditions. However, this needs to
be verified in younger patients. Third, VTE treatment has
changed since this cohort was constituted; that is, direct
oral anticoagulants have replaced vitamin K antagonists
for most patients. Therefore, it is unclear whether the
results can be extrapolated to patients treated with direct
oral anticoagulants. Fourth, as we enrolled patients with
VTE in inpatient and outpatient hospital services, the
proportion of patients with PE was relatively high, and
represented 69% of our study sample. Fifth, Gas6 testing
was performed only at the time of the index VTE and
12 months later, when 50% of the patients were still
receiving oral anticoagulation. Because we and others [21]
have demonstrated that Gas6 levels are affected by oral anti-
coagulation with vitamin K antagonists, we can assume that
the signiﬁcantly lower Gas6 level 12 months after the index
VTE was at least partly attributable to the anti-vitamin K
effect. Interestingly, Gas6 levels in the subgroup of patients
not receiving oral anticoagulation at this time point were sig-
niﬁcantly lower than those in patients receiving anticoagula-
tion. Thus, the correct interpretation of Gas6 levels would
require patients to interrupt anticoagulation, exposing those
with increased risk to the possibility of a VTE recurrence.
Finally, even though we adjusted our analyses for many
covariates, we might have missed important predictor
variables.
In conclusion, in the elderly, a high Gas6 level is asso-
ciated with higher risks of VTE recurrence and major
bleeding, but only up to 6 months, a period of time dur-
ing which most patients were still anticoagulated, and
death. Our data suggest that a clinical decision to avoid
prolonged anticoagulation could be attempted on the
basis of Gas6 plasma levels in the elderly. Further studies
are required to confirm whether the use of Gas6 levels for
adjusting the length of anticoagulation leads to better
outcomes, especially in younger patients.
Table 5 Association between growth arrest-specific gene 6 (Gas6) plasma level and overall mortality up to 36 months
n/N (%)
Crude hazard ratio
(95% confidence interval) P-value
Adjusted hazard ratio
(95% confidence interval) P-value
From the time of the index VTE (T1) onwards using Gas6 measured at the time of VTE diagnosis (T1)
Gas6 at the time of the index VTE (categorized)
Low (< 109%) 20/216 (9.3) Reference Reference
Medium (109–157%) 73/435 (16.8) 1.96 (1.20–3.19) 0.007 1.69 (1.00–2.84) 0.048
High (> 157%) 77/213 (36.2) 4.95 (3.04–8.05) < 0.001 3.44 (2.03–5.82) < 0.001
Log-transformed Gas6 at the time of the index VTE
Continuous (per log unit) 170/864 (19.7) 7.21 (4.48–11.60) < 0.001 5.00 (3.16–7.92) < 0.001
From the time of the index VTE onwards using Gas6 as a time-varying covariate (at the time of the index VTE and 12 months later)
Gas6 time-varying covariate (categorized)
Low (< 109%) Reference Reference
Medium (109–157%) 1.88 (1.26–2.80) 0.002 1.68 (1.09–2.57) 0.017
High (> 157%) 5.55 (3.63–8.47) < 0.001 3.55 (2.21–5.71) < 0.001
Log-transformed Gas6 time-varying covariate
Continuous (per log unit) 8.50 (5.51–13.11) < 0.001 5.18 (3.17–8.46) < 0.001
VTE, venous thromboembolism. Adjustments: mortality was adjusted for age, gender, cancer, provoked VTE, prior VTE, overt pulmonary
embolism, renal disease, history of major bleeding, heart failure, chronic lung disease, high pulse, low blood pressure, low oxygen, and periods
of anticoagulation as a time-varying covariate [49,53].
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